. 2023 Oct 31;12(21):6870. doi: 10.3390/jcm12216870

Table 4.

Severity of LUTS according to the IPSS questionnaire and SNPs genotypes.

Variables		IPSS Score		Allele Positivity Odds Ratio (95% Confidence Interval)
Variables		Mild/Moderate <20, n (%)	Severe ≥20, n (%)	Allele Positivity Odds Ratio (95% Confidence Interval)
Gender	Male	25 (54.3)	21 (47.5)	0.42 (0.18–0.97); p = 0.039
Gender	Female	40 (74.1)	14 (25.9)	0.42 (0.18–0.97); p = 0.039
rs2052129 (c.691G>T)	GG	30 (76.9)	9 (23.1)	2.48 (1.01–6.10); p = 0.046
rs2052129 (c.691G>T)	GT-TT	35 (57.4)	26 (42.6)	2.48 (1.01–6.10); p = 0.046
rs10156191 (p.Thr16Met)	CC	26 (76.5)	8 (23.5)	2.25 (0.89–5.71); p = 0.084
rs10156191 (p.Thr16Met)	CT-TT	39 (59.1)	27 (40.9)	2.25 (0.89–5.71); p = 0.084
rs1049742 (p.Ser332Phe)	CC	38 (71.7)	15 (28.3)	1.88 (0.82–4.31); p = 0.136
rs1049742 (p.Ser332Phe)	CT-TT	27 (57.4)	20 (42.6)	1.88 (0.82–4.31); p = 0.136
rs1049743 (p.His664Asp)	CC	30 (73.2)	11 (26.8)	1.87 (0.79–4.44); p = 0.153
rs1049743 (p.His664Asp)	CG-GG	35 (59.3)	24 (40.7)	1.87 (0.79–4.44); p = 0.153
rs2052129 rs10156191	No	33 (78.6)	9 (21.4)	2.98 (1.21–7.33); p = 0.015
rs2052129 rs10156191	Yes	32 (55.2)	26 (44.8)	2.98 (1.21–7.33); p = 0.015
SNPs	<4 SNPs	50 (72.5)	19 (27.5)	2.81 (1.16–6.77); p = 0.020
SNPs	4 SNPs	15 (48.4)	16 (51.6)	2.81 (1.16–6.77); p = 0.020
Homozygosity	No	59 (67.8)	38 (32.2)	2.46 (0.76–8.00); p = 0.210
Homozygosity	Yes	6 (46.2)	7 (53.8)	2.46 (0.76–8.00); p = 0.210

IPSS: International Prostate Symptom Score; Allele positivity compares the presence of the minor allele (either in heterozygosity or homozygosity) related to reduced DAO activity vs. the absence of the minor allele.